Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability
Type 2 Diabetes Mellitus
Enrolment: 27 · Results not recorded
Loading the evidence…
Drug · Dipeptidyl peptidase IV inhibitor (INHIBITOR; direct interaction)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Type 2 Diabetes Mellitus
Enrolment: 27 · Results not recorded
Diabetes Mellitus
Enrolment: 441 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 230 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 339 · Results not recorded
Diabetes Mellitus, Type 2
Enrolment: 593 · Results not recorded
Surveillance
Enrolment: 1096 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 500 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 3281 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute hepatic injury and hepatic encephalopathy induced by high-dose paracetamol; dose not stated in the abstract
Alogliptin and silymarin both reversed most paracetamol-induced hepatotoxicity, apoptosis and inflammation markers and improved memory performance, with alogliptin more effective at reducing TGF-beta 1, alpha smooth muscle actin, TNF-alpha and alkaline phosphatase and increasing percentage alternat…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.